← Eichor
Study identifier: NCT05264051 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Condition: Liver Diseases  ·  Sponsor: University of Chicago

PhaseN/A
Planned participants1200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

This description comes directly from the study's public registry record.

Talk to the study team

Omar Jamil, MD  ·  847-373-2360  ·  Omar.Jamil@uchospitals.edu

Maria Newsome  ·  773-702-2788  ·  mnewsome1@bsd.uchicago.edu

Always discuss trial participation with your own doctor first.

Locations (1)

The University of ChicagoChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05264051